Compass Pathways Plc (NASDAQ: CMPS) Q4 2024 Earnings Call Feb 27, 2025, 8:00 a.m. ET ...

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Elon Musk's chaotic appearance at CPAC on Thursday caused Google searches for the phrase "is Elon Musk on drugs" to spike the ...

It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 8.9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Months after Massachusetts voters rejected a ballot question that would permit adults to use and grow certain psychedelic drugs, some state lawmakers have begun proposing bills to legalize psilocybin.

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...